Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ebola:

The Pathogenesis of Ebola Virus Disease. Baseler L et al. Annu Rev Pathol. (2017)

Ebola virus: current and future perspectives. Jadav SS et al. Infect Disord Drug Targets. (2015)

Ebola vaccine and treatment. Takada A et al. Uirusu. (2015)

Search results

Items: 1 to 20 of 8688

1.

Ebola Virus Uptake into Polarized Cells from the Apical Surface.

Hu M, Wang F, Li W, Zhang X, Zhang Z, Zhang XE, Cui Z.

Viruses. 2019 Dec 2;11(12). pii: E1117. doi: 10.3390/v11121117.

2.

Pair-based likelihood approximations for stochastic epidemic models.

Stockdale JE, Kypraios T, O'Neill PD.

Biostatistics. 2019 Dec 6. pii: kxz053. doi: 10.1093/biostatistics/kxz053. [Epub ahead of print]

PMID:
31808813
3.

Ebola virus disease: An emerging and re-emerging viral threat.

Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Ansari AA, Gershwin ME, Anaya JM.

J Autoimmun. 2019 Dec 2:102375. doi: 10.1016/j.jaut.2019.102375. [Epub ahead of print] Review.

4.

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.

Du X, Zuo X, Meng F, Wu F, Zhao X, Li C, Cheng G, Qin FX.

Biochem Biophys Res Commun. 2019 Dec 2. pii: S0006-291X(19)32185-0. doi: 10.1016/j.bbrc.2019.11.065. [Epub ahead of print]

PMID:
31806372
5.

Correction to: Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model.

Poliquin G, Funk D, Jones S, Tran K, Ranadheera C, Hagan M, Tierney K, Grolla A, Dhaliwal A, Bello A, Leung A, Nakamura C, Kobasa D, Falzarano D, Garnett L, Bovendo HF, Feldmann H, Kesselman M, Hansen G, Gren J, Risi G, Biondi M, Mortimer T, Racine T, Deschambault Y, Aminian S, Edmonds J, Saurette R, Allan M, Rondeau L, Hadder S, Press C, DeGraff C, Kucas S, Cook BWM, Hancock BJ, Kumar A, Soni R, Schantz D, McKitrick J, Warner B, Griffin BD, Qiu X, Kobinger GP, Safronetz D, Stein D, Cutts T, Kenny J, Soule G, Kozak R, Theriault S, Menec L, Vendramelli R, Higgins S, Banadyga L, Liu G, Rahim MN, Kasloff S, Sloan A, He S, Tailor N, Albietz A, Pickering B, Wong G, Gray M, Strong JE.

Intensive Care Med Exp. 2019 Dec 4;7(1):66. doi: 10.1186/s40635-019-0283-9.

PMID:
31802320
6.

Rousette Bat Dendritic Cells Overcome Marburg Virus-Mediated Antiviral Responses by Upregulation of Interferon-Related Genes While Downregulating Proinflammatory Disease Mediators.

Prescott J, Guito JC, Spengler JR, Arnold CE, Schuh AJ, Amman BR, Sealy TK, Guerrero LW, Palacios GF, Sanchez-Lockhart M, Albariño CG, Towner JS.

mSphere. 2019 Dec 4;4(6). pii: e00728-19. doi: 10.1128/mSphere.00728-19.

7.

Risk estimation of Ebola virus disease outbreak in the Republic of Korea: using mathematical model and stochastic simulation.

Ko Y, Lee S, Kim S, Ki M, Jung E.

Epidemiol Health. 2019 Nov 24:e2019048. doi: 10.4178/epih.e2019048. [Epub ahead of print]

8.

Non-communicable diseases in the Western Area District, Sierra Leone, following the Ebola outbreak.

Koroma IB, Javadi D, Hann K, Harries AD, Smart F, Samba T.

Version 2. F1000Res. 2019 Jun 6 [revised 2019 Jan 1];8:795. doi: 10.12688/f1000research.18563.2. eCollection 2019.

9.

Trust, and distrust, of Ebola Treatment Centers: A case-study from Sierra Leone.

Richards P, Mokuwa E, Welmers P, Maat H, Beisel U.

PLoS One. 2019 Dec 2;14(12):e0224511. doi: 10.1371/journal.pone.0224511. eCollection 2019.

10.

The socio-economic distribution of exposure to Ebola: Survey evidence from Liberia and Sierra Leone.

Grépin KA, Poirier MJP, Fox AM.

SSM Popul Health. 2019 Nov 15;10:100472. doi: 10.1016/j.ssmph.2019.100472. eCollection 2020 Apr.

11.

Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors.

Odhar HA, Rayshan AM, Ahjel SW, Hashim AA, Albeer AAMA.

Bioinformation. 2019 Oct 8;15(9):627-632. doi: 10.6026/97320630015627. eCollection 2019.

12.

Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report.

Davis C, Tipton T, Sabir S, Aitken C, Bennett S, Becker S, Evans T, Fehling SK, Gunson R, Hall Y, Jackson C, Johanssen I, Kieny MP, McMenamin J, Spence E, Strecker T, Sykes C, Templeton K, Thorburn F, Peters E, Henao Restrepo AM, White B, Zambon M, Carroll MW, Thomson EC.

Clin Infect Dis. 2019 Nov 30. pii: ciz1165. doi: 10.1093/cid/ciz1165. [Epub ahead of print]

PMID:
31784751
13.

Accurate forecasts of the effectiveness of interventions against Ebola may require models that account for variations in symptoms during infection.

Hart WS, Hochfilzer LFR, Cunniffe NJ, Lee H, Nishiura H, Thompson RN.

Epidemics. 2019 Dec;29:100371. doi: 10.1016/j.epidem.2019.100371. Epub 2019 Sep 11.

14.

Forecasting the 2014 West African Ebola Outbreak.

Carias C, O'Hagan JJ, Gambhir M, Kahn EB, Swerdlow DL, Meltzer MI.

Epidemiol Rev. 2019 Nov 29. pii: mxz013. doi: 10.1093/epirev/mxz013. [Epub ahead of print]

PMID:
31781750
15.

Attacks on Ebola sites in DRC leave four workers dead.

Mahase E.

BMJ. 2019 Nov 28;367:l6750. doi: 10.1136/bmj.l6750. No abstract available.

PMID:
31780450
16.

Conference Report: Global Health Security Alliance (GLoHSA), a Product of the World Health Summit.

Quinn JM, Haggenmiller C, Wilson JM, McNamara T, Goebbels S, Hansen JC, Opitz A, Bourdeaux M, Sullivan R.

Disaster Med Public Health Prep. 2019 Nov 29:1-3. doi: 10.1017/dmp.2019.118. [Epub ahead of print]

PMID:
31779734
17.

Ebola Vaccine Trials: Progress in Vaccine Safety and Immunogenicity.

Matz KM, Marzi A, Feldmann H.

Expert Rev Vaccines. 2019 Nov 29. doi: 10.1080/14760584.2019.1698952. [Epub ahead of print]

PMID:
31779496
18.

A Framework for Discovering Health Disparities among Cohorts in an Influenza Epidemic.

Wang L, Chen J, Marathe A.

World Wide Web. 2019 Nov;22(6):2997-3020. doi: 10.1007/s11280-018-0608-8. Epub 2018 Jun 14.

PMID:
31777450
19.

Ebola virus vaccine receives prequalification.

Burki T.

Lancet. 2019 Nov 23;394(10212):1893. doi: 10.1016/S0140-6736(19)32905-8. No abstract available.

PMID:
31777382
20.

Developing vaccines against epidemic-prone emerging infectious diseases.

Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi H, Kumar A, Holst J, Clark C, Cramer JP, Røttingen JA, Hattchet R, Saville M, Norheim G.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019 Nov 27. doi: 10.1007/s00103-019-03061-2. [Epub ahead of print] Review.

PMID:
31776599

Supplemental Content

Loading ...
Support Center